Collaborations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from Research Services and Therapeutics	$ 59,239	$ 48,057
Deferred Revenue Current	66,103		$ 71,255
Cost Of Revenue	28,542	25,563
Accounts Payable and Other Accrued Liabilities, Current	33,029		31,953
G S K
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from Research Services and Therapeutics	11,200	11,800
Deferred Revenue Current	18,900		30,100
Deferred Revenue Noncurrent	0		0
Receivables, Net, Current	0		0
Research and development expense	6,000	1,800
Cost Of Revenue	400	$ 400
Accounts Payable and Other Accrued Liabilities, Current	$ 13,500		$ 11,500